liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Prostate-Specific Antigen for Prostate Cancer Staging in a Population-based Register
Linköping University, Department of Biomedicine and Surgery, Urology. Linköping University, Faculty of Health Sciences.
Regional Oncological Centre, Uppsala University, Sweden.
Department of Urology, Sahlgrenska Hospital, Gothenburg, Sweden.
Department of Urology, Sahlgrenska Hospital, Gothenburg, Sweden.
Show others and affiliations
2002 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 36, no 2, 99-105 p.Article in journal (Refereed) Published
Abstract [en]

Objective: Previous studies have shown a relationship between serum prostate-specific antigen (PSA) level and prostate tumour volume. Reports based on selected case series have also indicated that serum PSA may be used for staging, although a varying prevalence of metastasizing tumours complicates the interpretation of these studies. In order to determine the accuracy of the serum level of PSA in predicting the presence of metastases we performed a prospective cohort study of a geographically defined population of men with prostate cancer.

Methods: Serum level of PSA and the results of investigations for regional lymph node and distant metastases were recorded for all 8328 men with prostate cancer registered in the Swedish National Prostate Cancer Register 1996-1997.

Results: The prevalence of lymph node metastases among men who had undergone lymph node exploration was 4%, 16% and 33% for well, moderately and poorly differentiated tumours. The corresponding prevalence of distant metastases was 12%, 30% and 48%. With serum PSA <20 ng/ml as a cut-off point the negative likelihood ratios for well and moderately differentiated tumours were found to be 0.47 and 0.45 for lymph node metastases and 0.24 and 0.18 for distant metastases, resulting in post-test probabilities >92% for the exclusion of metastases. In men with poorly differentiated tumours, the negative likelihood ratio would need to be even lower to safely exclude disseminated disease.

Conclusion: For well to moderately differentiated tumours, further investigations to assess the presence of metastases may be omitted with no great risk for understaging if serum PSA <20 ng/ml.

Place, publisher, year, edition, pages
2002. Vol. 36, no 2, 99-105 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-25341DOI: 10.1080/003655902753679373Local ID: 9783OAI: diva2:245670
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2012-09-05Bibliographically approved
In thesis
1. Diagnosis, management, quality of life, and long-term survival in prostate cancer patients: A study based on national, regional, and local cancer registry data in Sweden
Open this publication in new window or tab >>Diagnosis, management, quality of life, and long-term survival in prostate cancer patients: A study based on national, regional, and local cancer registry data in Sweden
2001 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Prostate cancer is a common disease with considerable variaton in clinical behaviour and therapeutic responsiveness. Uncertainty surrounds almost all aspects of prostate cancer management and it has been difficult to conduct proper randomised controlled trials required for reliable evidence-based decision-making. Although randomised controlled trials are under way and may eventually provide unbiased data on the efficacy of the management of prostate cancer in selected patient groups under optimal circumstances, population-based studies are necessary to evaluate variations in incidence and the effectiveness of management as practised in the community at large.

This study uses three prospectively assembled population-based cohorts and one cross-sectional group of men with prostate cancer:

1. a local register of all men with prostate cancer in the Central District of Östergotland 1974-1986 (n=813)

2. the South-East Region Prostate Cancer Register 1987-1996 (n=6782)

3. the National Prostate Cancer Register 1996-1997 (n=8328)

4. A cross-sectional group of all men with prostate cancer residing in Östergotland 1999 comprising patients from cohorts 1 and 2 (n=1442)

The incidence of prostate cancer in the South-East Region increased from 613 in 1987 to 780 in 1993 and then slowly declined. The age-adjusted incidence varied from 89/100 000 to 169/100 000 between the different counties included in the National Prostate Cancer Register 1996. In counties where a large percentage of the tumours were detected when still localised, the incidence was higher and the men younger at diagnosis (both p<0.05). In the age interval 50-59 years of age the median PSA was 13 ng/ml, whereas it was 35 ng/ml in those younger than 50. This difference was significant (p<0.05) and is probably explained by larger total tumour volume among men in the youngest age group. For men with well to moderately differentiated tumours and PSA < 20 ng/ml the risk for regional and distant metastases was below 10%. Between 1987 and 1996 the proportion of men treated with radical prostatectomy in the South-East Region decreased from 11% to 2.5%. During the same period the percentage of patients receiving GnRH-analogues increased from 3.9% to 37.8% while the percentage of patients treated with orchiectomy decreased from 40.0% to 12.8%. For patients treated with radiotherapy the median PSA was 16.7 ng/ml, for those who underwent radical prostatectomy 9.3 ng/ml, for patients receiving GnRH-analogues 61 ng/ml and for those treated with bilateral orchiectomy it was 88 ng/ml. All differences in PSA levels between the treatment groups were significant (p<0.05), indicating that there is a selection process with men having less advanced cancer receiving GnRH-analogues and men with more advanced cancer undergoing bilateral orchiectomy, and similarly a selection of men with smaller tumours being treated with radical prostatectomy rather than radiotherapy. Of the men answering the questionnaire sent to all prostate cancer patients residing in Ostergotland 1999 42% had perceived pain during the previous week and 26% stated their quality of life to be 50% or less on a visual analogue scale. A high health-care availability rating and short time since diagnosis were found to significantly predict lower rating of pain on average (p<0.05). Pain on average was found to be a significant predictive factor for decreased quality of life together with high age, low healthcare availability rating and palliative treatment (p<0.05). Age ≥ 70 years, advanced stage and poor differentiation were risk factors associated with increased risk for prostate cancer death in Östergotland Central District Cohort (p<0.05). The survival curve followed a continuous exponential course throughout the period of observation.

The geographical as well as temporal variations in incidence are probably explained by differences in diagnostic activity, which also affects the age at diagnosis and distribution of stages. There are also large disparities in management within the country, which reflects the lack of evidence supporting one treatment in favour of another. How diagnostic activity and different local habits in management affect outcome in the long run is still unknown, but the results of our study regarding quality of life and survival may be used as a basis for management decision-making. Patients with localised tumours have a favourable prognosis, even without initial treatment. When deciding on therapy, however, the grade of malignancy should be taken into account as it has a great influence on disease-specific survival. For men with well to moderately differentiated tumours and PSA < 20 ng/ml, further investigation to exclude distant and regional metastases is unnecessary.

Place, publisher, year, edition, pages
Linköping: Linköpings universitet, 2001. 94 p.
Linköping University Medical Dissertations, ISSN 0345-0082 ; 664
National Category
Medical and Health Sciences
urn:nbn:se:liu:diva-25708 (URN)10084 (Local ID)91-7219-765-X (ISBN)10084 (Archive number)10084 (OAI)
Public defence
2001-04-06, Berzeliussalen, Universitetssjukhuset, Linköping, 09:00 (Swedish)
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2012-09-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Varenhorst, Eberhard
By organisation
UrologyFaculty of Health Sciences
In the same journal
Scandinavian Journal of Urology and Nephrology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 45 hits
ReferencesLink to record
Permanent link

Direct link